Lucira Health, Inc. (NASDAQ:LHDX – Get Rating)'s stock price was down 9.9% during mid-day trading on Tuesday . The company traded as low as $0.20 and last traded at $0.23. Approximately 525,450 shares changed hands during mid-day trading, a decline of 98% from the average daily volume of 29,320,967 shares. The stock had previously closed at $0.25.

Lucira Health Price Performance

The company has a market capitalization of $9.03 million, a price-to-earnings ratio of -0.06 and a beta of 3.75. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.79 and a current ratio of 1.46. The business has a 50 day moving average price of $0.33 and a 200-day moving average price of $0.58.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Prudential Financial Inc. acquired a new position in Lucira Health during the 2nd quarter worth approximately $32,000. Renaissance Technologies LLC purchased a new stake in shares of Lucira Health during the second quarter worth $78,000. BlackRock Inc. lifted its position in shares of Lucira Health by 18.8% during the first quarter. BlackRock Inc. now owns 51,468 shares of the company's stock worth $183,000 after acquiring an additional 8,131 shares in the last quarter. AlphaCentric Advisors LLC purchased a new stake in shares of Lucira Health during the third quarter worth $339,000. Finally, Vanguard Group Inc. raised its position in shares of Lucira Health by 23.4% in the first quarter. Vanguard Group Inc. now owns 631,767 shares of the company's stock worth $2,256,000 after buying an additional 119,929 shares in the last quarter. 57.02% of the stock is owned by institutional investors and hedge funds.

About Lucira Health

(Get Rating)

Lucira Health, Inc, a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits.

Read More

• Get a free copy of the StockNews.com research report on Lucira Health (LHDX)
• After an Earnings Blowout, Is Ciena Stock a Buying Opportunity?
• Here's Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
• Meta Breaks Out Of A Base, Looks Like A Growth Stock Again
• The Bottom Is In For McCormick & Company
• Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story

Receive News & Ratings for Lucira Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucira Health and related companies with MarketBeat.com's FREE daily email newsletter.